Cytoskeletal Protein Variants Driving Atrial Fibrillation: Potential Mechanisms of Action.
Stan W van WijkWei SuLeonoor F J M WijdeveldKennedy S RamosBianca J J M BrundelPublished in: Cells (2022)
The most common clinical tachyarrhythmia, atrial fibrillation (AF), is present in 1-2% of the population. Although common risk factors, including hypertension, diabetes, and obesity, frequently underlie AF onset, it has been recognized that in 15% of the AF population, AF is familial. In these families, genome and exome sequencing techniques identified variants in the non-coding genome (i.e., variant regulatory elements), genes encoding ion channels, as well as genes encoding cytoskeletal (-associated) proteins. Cytoskeletal protein variants include variants in desmin, lamin A/C, titin, myosin heavy and light chain, junctophilin, nucleoporin, nesprin, and filamin C. These cytoskeletal protein variants have a strong association with the development of cardiomyopathy. Interestingly, AF onset is often represented as the initial manifestation of cardiac disease, sometimes even preceding cardiomyopathy by several years. Although emerging research findings reveal cytoskeletal protein variants to disrupt the cardiomyocyte structure and trigger DNA damage, exploration of the pathophysiological mechanisms of genetic AF is still in its infancy. In this review, we provide an overview of cytoskeletal (-associated) gene variants that relate to genetic AF and highlight potential pathophysiological pathways that drive this arrhythmia.
Keyphrases
- atrial fibrillation
- copy number
- genome wide
- catheter ablation
- oral anticoagulants
- heart failure
- left atrial
- dna damage
- left atrial appendage
- dna methylation
- risk factors
- direct oral anticoagulants
- binding protein
- metabolic syndrome
- protein protein
- percutaneous coronary intervention
- oxidative stress
- gene expression
- amino acid
- climate change
- insulin resistance
- cardiovascular disease
- weight loss
- glycemic control
- weight gain
- human health
- coronary artery disease
- left ventricular
- venous thromboembolism
- mitral valve
- small molecule
- early onset